Oxford UK — ProImmune Ltd., a leader in epitope discovery, immunogenicity and immune monitoring products and services has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL™ Immunogenicity System, a suite of tools used in the design and selection of biological drugs at the preclinical stage.

Combined with ProImmune’s unique cell-free HLA-peptide binding assays for more than 50 class II HLA alleles, these new assays enable the creation of a detailed profile of the helper T cell immune response to one or more drug leads.

Unlike traditional assays which are based on radioactive thymidine incorporation, ProImmune’s new assays utilize powerful flow cytometry methods, enabling accurate determination of the percentage of proliferating CD4+ cells and detailed phenotyping of T cell responses, all with significantly improved overall sensitivity.

Dr. Nikolai Schwabe, CEO of ProImmune, said: “Our customers have come to expect ProImmune to deliver technology leadership without compromise. The launch of our CFSE T cell proliferation assays joins with our unequalled capability in class II HLA binding assays, delivering the most powerful in vitro assay platform on the market for assessing drug immunogenicity risk.”

For more information, please contact:

At ProImmune:

Dr Nikolai Schwabe, CEO

Tel: +44 (0)870 042 7279

Email: enquiries@proimmune.com

About ProImmune – www.proimmune.com

ProImmune is a private biotechnology company with its headquarters in Oxford, UK, that specializes in providing products and services for epitope discovery, immune monitoring and the design of biological drugs with reduced immunogenicity risk. ProImmune has a wide range of customers from leading pharmaceutical and biotechnology companies, as well as clinical and academic research institutes throughout the world.